Cogent Biosciences

We’re headed to the @Jefferies Global Healthcare Conference in London next week. You can listen to our presentation on Wednesday, November 19th at 11:30am GMT/6:30am ET here: https://bit.ly/4p4hPge #JefferiesHealthcare

Today we shared landmark top-line results from our Phase 3 PEAK trial in #GIST achieving 16.5 months median progression free survival with the bezuclastinb plus sunitinib combination compared to 9.2 months with sunitinib monotherapy. Our webcast will begin this morning at 8am ET. We invite you to join here: https://bit.ly/3Xlop6c and read the release: https://bit.ly/3JL9LlE. We are deeply grateful to the patients, families, and researchers whose participation in PEAK helped make this possible. 

Today we reported our third quarter 2025 financial results and recent business highlights. Read the press release https://bit.ly/4nwUAuh for more. We also announced two oral presentations and a poster with bezuclastinib at #ASH25 and a poster with our newest preclinical program, a JAK2 V617F mutant-selective inhibitor. Read about the abstracts here https://bit.ly/4hLBO10.

We were thrilled to share updated preclinical data from our potent and selective KRAS(ON) inhibitor at the 2025 EORTC-NCI-AACR Symposium last week in Boston. We’re looking forward to moving this program towards the clinic, with a potential IND in 2026. Read the release http://bit.ly/43uJYVn and view the poster http://bit.ly/3JpkGRH.

The Cogent team proudly came together in purple to recognize International Mastocytosis & Mast Cell Diseases Awareness Day — a day that unites patients, advocates, caregivers, healthcare providers, researchers, and industry partners around a shared mission: increasing awareness and driving progress for these rare diseases.   As part of our commitment to advancing research and bringing new treatment options to patients living with Systemic Mastocytosis, Cogent is honored to serve as a sponsor of this year’s campaign, “Be Informed, Be Connected.”   Learn more about the 2025 global initiative and how it’s helping to educate and empower the mast cell disease community: https://lnkd.in/eY4E8McU

We’re thrilled to announce that the FDA has granted Breakthrough Therapy Designation for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients previously treated with avapritinib as well as in patients with Smoldering Systemic Mastocytosis; populations with no currently approved standard of care. Our team has a busy few months ahead with PEAK top-line results expected in November and APEX top-line results expected in December 2025 as we prepare for filing our first New Drug Application by year-end. Read the press release here. http://bit.ly/4hjm7xD

This October, we’re celebrating five years of bold thinking, meaningful work, and the incredible people who make it all happen. We’ve come a long way — and we’re just getting started. Check out this short video for a look back at our journey and a glimpse of what’s ahead. Thank you to our team for being part of the story. Here’s to the next five! 🚀 #TeamCogent #LifeAtCogent

We’re proud to be one of this year’s sponsors of the European Competence Network on Mastocytosis (ECNM) annual meeting. The team is here and looking forward to connecting with systemic #mastocytosis disease experts. #NonAdvSM #AdvSM

Our Medical Affairs team is at the 2025 Society of Hematologic Oncology Annual Meeting (SOHO 2025) in Houston. Stop by booth #118 to learn more. See you there! #NonAdvSM #AdvSM

Tune in next week on Wed, Sept 3 at 9:00am ET to listen to our fireside chat at Citi’s 2025 Biopharma Back-to-School Conference. Register and join here http://bit.ly/3HFbBDF.